Amanote Research
Register
Sign In
Aberrant Hyperediting of Myeloma Transcriptome by Adar1 Confers Oncogenicity and Is a Marker of Poor Prognosis
Hematological Oncology
- United Kingdom
doi 10.1002/hon.237_2631
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2019
Authors
P. Teoh
O. An
T. Chung
J. Chooi
S. Toh
S. Fan
W. Wang
B. Koh
M. Fullwood
M. Ooi
S. de Mel
C. Soekojo
P. Chen
S. Ng
H. Yang
W. Chng
Publisher
Wiley
Related search
IL6R-STAT3-ADAR1 (P150) Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma
Haematologica
Hematology
Epstein-Barr Virus Infection Is Associated With Clinical Characteristics and Poor Prognosis of Multiple Myeloma
Bioscience Reports
Biochemistry
Cell Biology
Molecular Biology
Biophysics
Cathepsin D Is a Potential Serum Marker for Poor Prognosis in Glioma Patients
Cancer Research
Cancer Research
Oncology
ASPM Is a Novel Marker for Vascular Invasion, Early Recurrence, and Poor Prognosis of Hepatocellular Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Overexpression of COL3A1 Confers a Poor Prognosis in Human Bladder Cancer Identified by Co-Expression Analysis
Oncotarget
Oncology
P2.09-32 Detached Epithelial Cell Cluster Size in Lung Adenocarcinoma Is a Marker of Poor Prognosis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Aberrant GRK6 Promoter Methylation Is Associated With Poor Prognosis in Hypopharyngeal Squamous Cell Carcinoma
Oncology Reports
Medicine
Cancer Research
Oncology
LAPTM4B Allele *2 Is a Marker of Poor Prognosis Following Hepatic Tumor Resection for Hepatocellular Carcinoma
PLoS ONE
Multidisciplinary
Aberrant Expression of KPNA2 Is Associated With a Poor Prognosis and Contributes to OCT4 Nuclear Transportation in Bladder Cancer
Oncotarget
Oncology
